BioSpace News Archive

We are excited to announce that our new toxicology facility in Suzhou, China has achieved a key milestone when Jiangsu’s Provincial Department of Science and Technology granted the site an “Experimental Animal Use License” on January 21, 2022, following an on-site inspection and review of recently completed construction.

GreenLight Biosciences (“GreenLight”), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture, and Environmental Impact Acquisition Corp. (Nasdaq: ENVI) (“ENVI”), a special purpose acquisition company, yesterday announced the closing of their previously announced business combination.

The Aicardi-Goutières Syndrome Americas Association, LunaPBC, and Genetic Alliance announced a program to assemble a patient-led drug discovery community studying the disease etiology of a rare neurodevelopmental disorder known as Aicardi-Goutières syndrome and support development of therapeutic treatments for this devastating disease.

Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted its New Drug Application (“NDA”) resubmission for TLANDO® (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”).

Piezo Motion, a Brain Scientific company, and Applied Mechatronics announce a partnership.

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences

Candel Therapeutics, Inc. today announced that Francesca Barone, M.D., Ph.D., has been named as the company’s Chief Scientific Officer.

AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 9:20 a.m. eastern time.

Artivion, Inc. announced today that fourth quarter and full year 2021 financial results will be released on Thursday, February 17, 2022 after the market closes.

Neuropeak Pro, a Precision Breathing, Heart Rate Variability (HRV) and brain performance company that trains elite athletes to enhance performance under pressure, introduced today the first-of-its-kind mobile, real-time precision breathing training device and performance app designed to unlock optimum performance.